CVM Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to CEL-SCI's net margin of --. CEL-SCI's return on equity of -- beat Perspective Therapeutics's return on equity of --.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 2514.38%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 638.1%. Given that CEL-SCI has higher upside potential than Perspective Therapeutics, analysts believe CEL-SCI is more attractive than Perspective Therapeutics.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. CEL-SCI's net income of -$7.1M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, CEL-SCI's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 12.62x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to CEL-SCI's net margin of -711.67%. CEL-SCI's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 2514.38%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1286.4%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.449, suggesting its more volatile than the S&P 500 by 44.948%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. CEL-SCI's net income of -$7.1M is lower than IGC Pharma's net income of -$1.8M. Notably, CEL-SCI's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 16.43x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to CEL-SCI's net margin of -49.65%. CEL-SCI's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 2514.38%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that CEL-SCI has higher upside potential than NovaBay Pharmaceuticals, analysts believe CEL-SCI is more attractive than NovaBay Pharmaceuticals.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. CEL-SCI's net income of -$7.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, CEL-SCI's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

National Healthcare has a net margin of -- compared to CEL-SCI's net margin of 1.65%. CEL-SCI's return on equity of -- beat National Healthcare's return on equity of 10.72%.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 2514.38%. On the other hand National Healthcare has an analysts' consensus of -- which suggests that it could fall by --. Given that CEL-SCI has higher upside potential than National Healthcare, analysts believe CEL-SCI is more attractive than National Healthcare.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison National Healthcare has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.822%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Healthcare offers a yield of 2.66% to investors and pays a quarterly dividend of $0.61 per share. CEL-SCI pays -- of its earnings as a dividend. National Healthcare pays out 36.27% of its earnings as a dividend. National Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CEL-SCI quarterly revenues are --, which are smaller than National Healthcare quarterly revenues of $369.4M. CEL-SCI's net income of -$7.1M is lower than National Healthcare's net income of $6.1M. Notably, CEL-SCI's price-to-earnings ratio is -- while National Healthcare's PE ratio is 14.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 1.10x for National Healthcare. Usually stocks with elevated PS ratios are considered overvalued.